News &amp; Updates

Switching from butter to plant-based oils such as olive, soybean, or canola may help prevent premature deaths, as reported in a study.

Replacing butter with plant-based oils good for longevity

Radiotherapy plus short-course ADT confers survival benefit in oligometastatic prostate cancer

In patients with oligometastatic hormone-sensitive prostate cancer, the combination of stereotactic body radiotherapy (SBRT) plus a short course of androgen deprivation therapy (ADT) appears to improve progression-free survival (PFS), according to the phase II RADIOSA trial.

Radiotherapy plus short-course ADT confers survival benefit in oligometastatic prostate cancer

Efficacy benefit of nivolumab plus cabozantinib combo in aRCC continues through final results

11 Mar 2025 by

The long-term efficacy benefit of the nivolumab and cabozantinib combination vs sunitinib as a frontline treatment for aRCC is observed through the final results of CheckMate 9ER, with the report covering a minimum follow-up of 5 years first presented at ASCO GU 2025

Efficacy benefit of nivolumab plus cabozantinib combo in aRCC continues through final results

Allergy history, previous exposure predict oxaliplatin hypersensitivity reactions

A history of allergy, previous oxaliplatin exposure, and chemotherapy regimens are associated with a higher risk of oxaliplatin hypersensitivity reactions in patients with colorectal cancer, reveals a study.

Allergy history, previous exposure predict oxaliplatin hypersensitivity reactions

Original New Drug Application Approvals by US FDA (1-15 February 2025)

New drug applications approved by US FDA as of 1-15 February 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 February 2025)

Adjuvant nivolumab delivers in muscle-invasive bladder cancer

09 Mar 2025 by

Adjuvant nivolumab appears to improve survival outcomes in patients with muscle-invasive bladder cancer (MIBC) who have undergone radical surgery, regardless of prior exposure to neoadjuvant chemotherapy, according to additional data from the phase III CheckMate 274 trial.

Adjuvant nivolumab delivers in muscle-invasive bladder cancer

09 Mar 2025

Sustained PFS benefit in breast cancer with palbociclib + exemestane with ovarian function suppression

09 Mar 2025

Treatment with palbociclib plus exemestane with ovarian function suppression does not appear to produce improvements in overall survival (OS), although it yields sustained increases in progression-free survival (PFS) as compared with capecitabine in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer, according to updated data from the phase II Young-PEARL study.

Sustained PFS benefit in breast cancer with palbociclib + exemestane with ovarian function suppression

09 Mar 2025

Survival in mCRPC prolonged with talazoparib–enzalutamide combo

08 Mar 2025 by

The combination of the PARP inhibitor talazoparib plus the androgen receptor-pathway inhibitor enzalutamide yields a clinically meaningful increase in the overall survival of patients with metastatic castration-resistant prostate cancer (mCRPC) being treated in the first-line setting when compared with enzalutamide alone, according to final data from the phase III TALAPRO-2 trial.

Survival in mCRPC prolonged with talazoparib–enzalutamide combo

08 Mar 2025

Cabozantinib plus ipilimumab/nivolumab fails to meet efficacy target in thyroid cancer

Treatment with cabozantinib in combination with nivolumab and ipilimumab (CaboNivoIpi) results in low objective response rates (ORRs) and a high rate of grade ≥3 treatment-related adverse events (AEs) among patients with previously treated advanced differentiated thyroid cancer, reveals a recent study.

Cabozantinib plus ipilimumab/nivolumab fails to meet efficacy target in thyroid cancer

$Seizure freedom may be achieved with surgery in kids with refractory epilepsy, brain tumours$

Seizure freedom may be achieved with surgery in kids with refractory epilepsy, brain tumours

Epilepsy surgery appears beneficial for children with refractory epilepsy and high-grade central nervous system tumours, with a multicentre study showing that the procedure results in seizure freedom in most patients.

Seizure freedom may be achieved with surgery in kids with refractory epilepsy, brain tumours